ARTICLE | Clinical News
PulmoXen: Phase I data
April 14, 2014 7:00 AM UTC
An open-label, Russian Phase I trial in 12 healthy volunteers showed that once-daily 2,500 and 5,000 IU doses of inhaled PulmoXen for 7 days were well tolerated. Pharmsynthez, which conducted the tria...